Elsevier Inc.

SHERPA: Unknown

People

  1. Aghajanian
    Aghajanian
  2. Abu-Rustum
    Abu-Rustum
  3. Chi
    Chi
  4. Hensley
    Hensley
  5. O'Cearbhaill
    O'Cearbhaill
  6. Tew
    Tew
  7. Iasonos
    Iasonos
  8. Sonoda
    Sonoda
  9. Sabbatini
    Sabbatini
  10. Alektiar
    Alektiar

Groups

  1. Gynecologic Medicine Service (302)
  2. Solid Tumor Oncology Division (302)
  3. Department of Medicine (301)
  4. Gynecology Disease Management Team (274)
  5. GDMT, Medicine (272)
  6. Surgery (151)
  7. GDMT, Surgery (133)
  8. Epidemiology and Biostatistics (73)
  9. Survivorship Research (71)
  10. Biostatistics Service (69)
Search Within
  1. "Journal article"
  2. "Gynecologic Medicine Service"
Formats
  1. Journal Article (302)
Groups
  1. Gynecologic Medicine Service (302)
  2. Solid Tumor Oncology Division (302)
  3. Department of Medicine (301)
  4. Gynecology Disease Management Team (274)
  5. GDMT, Medicine (272)
  6. Surgery (151)

More Groups

People
  1. Carol Aghajanian (129)
  2. Nadeem Abu-Rustum (88)
  3. Dennis Chi (75)
  4. Martee Hensley (58)
  5. Richard Barakat (58)
  6. Paul Sabbatini (51)

More People

Years
  1. 2024 (4)
  2. 2023 (25)
  3. 2022 (17)
  4. 2021 (20)
  5. 2020 (18)
  6. 2019 (12)

More Years

Publications
  1. Gynecologic Oncology (232)
  2. Journal of Geriatric Oncology (20)
  3. Community Oncology (9)
  4. European Journal of Cancer (7)
  5. Clinical Breast Cancer (6)
  6. Seminars in Oncology (6)

More Publications

Results (302)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 2 trial of zanidatamab in HER2-overexpressed advanced endometrial carcinoma and carcinosarcoma (ZW25-IST-2)
    Journal Article

    Lumish, M.; Chui, M. H.; Zhou, Q.; Iasonos, A.; Sarasohn, D.; Cohen, S.; Friedman, C.; Grisham, R.; Konner, J.; Kyi, C.; more...
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • Mesonephric and mesonephric-like adenocarcinomas of gynecologic origin: A single-center experience with molecular characterization, treatment, and oncologic outcomes
    Journal Article

    Praiss, A. M.; White, C.; Iasonos, A.; Selenica, P.; Zivanovic, O.; Chi, D. S.; Abu-Rustum, N. R.; Weigelt, B.; Aghajanian, C.; Girshman, J.; more...
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • Targeting HER2-mutant metastatic cervical cancer with neratinib: Final results from the phase 2 SUMMIT basket trial
    Journal Article

    Friedman, C. F.; D'Souza, A.; Bello Roufai, D.; Tinker, A. V.; de Miguel, M.; Gambardella, V.; Goldman, J.; Loi, S.; Melisko, M. E.; Oaknin, A.; more...
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • Pathogenic germline variants in non-BRCA1/2 homologous recombination genes in ovarian cancer: Analysis of tumor phenotype and survival
    Journal Article

    Kahn, R. M.; Selenica, P.; Boerner, T.; Roche, K. L.; Xiao, Y.; Sia, T. Y.; Maio, A.; Kemel, Y.; Sheehan, M.; Salo-Mullen, E.; more...
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • Niraparib and dostarlimab for the treatment of recurrent platinum-resistant ovarian cancer: Results of a phase II study (MOONSTONE/GOG-3032)
    Journal Article

    Randall, L. M.; O'Malley, D. M.; Monk, B. J.; Coleman, R. L.; Gaillard, S.; Adams, S.; Duska, L. R.; Dalton, H.; Holloway, R. W.; Huang, M.; more...
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save
  • Isolated vaginal recurrence in women with stage I endometrial cancer
    Journal Article

    Rios-Doria, E.; Cun, H. T.; Filippova, O. T.; Mueller, J. J.; Alektiar, K. M.; Ellenson, L. H.; Makker, V.; Lakhman, Y.; Leitao, M. M. Jr; Jhingran, A.; more...
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save
  • TERT promoter mutations and gene amplification in endometrial cancer
    Journal Article

    Praiss, A. M.; Marra, A.; Zhou, Q.; Rios-Doria, E.; Momeni-Boroujeni, A.; Iasonos, A.; Selenica, P.; Brown, D. N.; Aghajanian, C.; Abu-Rustum, N. R.; more...
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save
  • A randomized phase 2 study of sapanisertib in combination with paclitaxel versus paclitaxel alone in women with advanced, recurrent, or persistent endometrial cancer
    Journal Article

    Han, S. N.; Oza, A.; Colombo, N.; Oaknin, A.; Raspagliesi, F.; Wenham, R. M.; Braicu, E. I.; Jewell, A.; Makker, V.; Krell, J.; more...
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save
  • Adverse events and oncologic outcomes with combination lenvatinib and pembrolizumab for the treatment of recurrent endometrial cancer
    Journal Article

    Zammarrelli, W. A. 3rd; Ma, W.; Espino, K.; Gordhandas, S.; Yeoshoua, E.; Ehmann, S.; Zhou, Q.; Iasonos, A.; Abu-Rustum, N. R.; Aghajanian, C.; more...
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save
  • Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer
    Journal Article

    Pignata, S.; Bookman, M.; Sehouli, J.; Miller, A.; Penson, R. T.; Taskiran, C.; Anderson, C.; Hietanen, S.; Myers, T.; Madry, R.; more...
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save